Spironolactone 25mg daily vs placebo

Study population:

Patients with heart failure  Patients had NYHA Class IV heart failure in the 6 months prior to enrolment, but were NYHA class III or IV at enrolment.

Comments:

The mean age of patients was 65 years.

Spironolactone also reduced the frequency of hospitalisation for heart failure and produced a significant improvement in the symptoms of heart failure.

Patients in the trial were on an ACE inhibitor (if tolerated) and a diuretic.  10% of patients were also on a beta-blocker.